Figure 3
Elevated expression of AEBP1 is associated with poor overall survival (OS) rate in patients with both early-stage (TNM I and II) and late-stage (TNM III and IV) gastric cancer. (A) Kaplan-Meier analysis of 166 patients with gastric cancer indicating high AEBP1 expression is associated with poor overall survival (P = 0.0004). (B) Kaplan-Meier analysis of 876 patients with gastric cancer from NCBI GEO database revealing AEBP1high patients had a significantly lower overall survival rate than those with AEBP1low tumors (P < 0.0001). (C) Kaplan-Meier analysis of 378 patients with gastric cancer from TCGA-STAD database indicating AEBP1high patients had a lower overall survival rate than those with AEBP1low tumors (P = 0.0267). (D) Kaplan-Meier analyses of patients with TNM I and II stage gastric cancer from our cohort showing high expression of AEBP1 is correlated with a lower overall survival rate (P = 0.0403). (E) Kaplan-Meier analyses from the NCBI GEO database in patients with TNM I (P = 0.2695) and TNM II (P = 0.0495) stage gastric cancer. (F) Kaplan-Meier estimation of patients with TNM III and IV stage gastric cancer from our cohort showing high expression of AEBP1 is correlated with a lower overall survival rate (P = 0.0294). (G) Kaplan-Meier analyses from NCBI GEO database in patients with TNM III (P < 0.0001) and TNM IV (P = 0.0047) stage gastric cancer.
